Protherics PLC
Notification of Director's Interests
London, UK; Brentwood, TN, US: 10 July 2008 - Protherics PLC
("Protherics" or the "Company"), the international biopharmaceutical
company focused on critical care and cancer, in accordance with
Sections 3.1.4R of the FSA Disclosure and Transparency
Rules, announces that 916,202 ordinary shares (the "Shares")
were issued to Jacques Gonella, Non-executive Director of Protherics,
on 9 July 2008 following their admission to the Official List of the
Financial Services Authority.
The Shares form part of the allotment of 1,741,911 ordinary shares
(details of which are contained in the Company's announcement dated 4
July 2008) made pursuant to the MacroMed Acquisition Agreement
(the "Agreement") approved by shareholders at the Company's
Extraordinary General Meeting held on 3 January 2007. Details of the
Agreement are contained in the Company's announcement dated 7 December
2006. In accordance with the Agreement the issue price of the
shares is 69.69 pence per share.
Following the issuance of the Shares, Dr Gonella holds a beneficial
interest in 9,162,017 ordinary shares in the
Company representing 2.677% of the issued share
capital of 342,159,034 ordinary shares.
/ Ends /
For further information please contact:
Protherics
Nick Staples, Director of Corporate Affairs +44 (0) 7919 480510
Julie Vickers, Company Secretary +44 (0)1928 518010
Financial Dynamics - press enquiries
London: Ben Atwell, Lara Mott +44 (0) 20 7831 3113
New York: John Capodanno +1 212 850 5600
Or visit www.protherics.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
Contact Information: Contacts: RNS Customer Services 0044-207797-4400 http://www.rns.com